Bardiès M, Bardet S, Faivre-Chauvet A, Peltier P, Douillard J Y, Mahé M, Fiche M, Lisbona A, Giacalone F, Meyer P, Gautherot E, Rouvier E, Barbet J, Chatal J F
INSERM Research Unit 211, Nantes, France.
J Nucl Med. 1996 Nov;37(11):1853-9.
The purpose of this study was to estimate the dose delivered to tumor targets and normal tissues after two-step injection of an anti-CEA/anti-DTPA-In (F6-734) bispecific antibody and a 131I-labeled di-DTPA in-TL bivalent hapten in patients with medullary thyroid carcinoma (MTC) and small-cell lung cancer (SCLC).
Five patients with persistent disease or recurrences of MTC and five patients with primary SCLC or relapse were studied. In a first step, 0.1 to 0.3 mg/kg of F6-734 bispecific antibody was injected intravenously. Four days later, 6 nmole (5.8 to 9.8 mCi) of 131I-labeled di-DTPA in-TL bivalent hapten were injected. Quantitative imaging was performed during one week after the second injection.
All 5 patients with MTC showed positive immunoscintigraphy (IS). In the smallest visualized and resected tumor (0.8 g), the fraction of injected activity per gram (% ID/g) was 0.1% at Day 3. IS was positive in 4 of the 5 patients with SCLC. The volume of the smallest visualized SCLC tumor was estimated at 11 +/- 2 ml, and tumor uptake was about 0.009% ID/g. Tumor dose estimates ranged from 4.2 to 174 cGy/mCi in patients with MTC and from 1.7 to 8 cGy/mCi in patients with SCLC.
High absorbed dose values were calculated for small MTC recurrences. For SCLC recurrences the values were smaller but in the same range as those obtained by other investigators with the one-step technique in lymphoma.
本研究的目的是估计在甲状腺髓样癌（MTC）和小细胞肺癌（SCLC）患者中，分两步注射抗CEA/抗二乙三胺五乙酸铟（F6 - 734）双特异性抗体和131I标记的二乙三胺五乙酸铟 - TL二价半抗原后，肿瘤靶区和正常组织所接受的剂量。
对5例持续性疾病或复发的MTC患者和5例原发性SCLC或复发患者进行了研究。第一步，静脉注射0.1至0.3mg/kg的F6 - 734双特异性抗体。4天后，注射6纳摩尔（5.8至9.8毫居里）的131I标记的二乙三胺五乙酸铟 - TL二价半抗原。在第二次注射后的一周内进行定量成像。
所有5例MTC患者的免疫闪烁显像（IS）均为阳性。在最小的可视且切除的肿瘤（0.8克）中，第3天时每克注射活性分数（%ID/g）为0.1%。5例SCLC患者中有4例的IS为阳性。最小可视SCLC肿瘤的体积估计为11±2毫升，肿瘤摄取约为0.009%ID/g。MTC患者的肿瘤剂量估计范围为4.2至174厘戈瑞/毫居里，SCLC患者为1.7至8厘戈瑞/毫居里。
对于小的MTC复发，计算出了高吸收剂量值。对于SCLC复发，该值较小，但与其他研究者在淋巴瘤中采用一步技术所获得的值处于同一范围。
